Dongrui Pharmaceutical (02348.HK) subsidiary obtains drug production registration approval for 50mg and 100mg sitagliptin tablets.

Zhitong Financial News APP reported that Dongrui Pharmaceutical (02348.HK) announced that its subsidiary, Suzhou Dongrui Pharmaceutical Co., Ltd., became the second company in China to obtain the drug production registration certificate for 50mg and 100mg acarbose tablets from the National Medical Products Administration. The tablets belong to the third category of chemical drugs and are considered equivalent through consistency evaluation. This product is an oral hypoglycemic agent for the treatment of type 2 diabetes in adults to improve blood sugar control.